What We Do
About Us
Cure Leukaemia was established in 2003 by Professor Charlie Craddock CBE and patients Graham Silk and Michael Woolley to allow patients with blood cancer in the Birmingham region to access remarkably effective new treatments which were then becoming available.
Since then, Cure Leukaemia has been able to expand to a national level, and we are now able to offer potential life-saving treatment to patients across the UK.
Thanks to our huge CL Family of dedicated fundraisers, we’ve been able to continue to grow each year and connect more patients to potentially lifesaving treatment.
What is a Clinical Trial?
The Trials Acceleration Programme (TAP)
In January 2020, Cure Leukaemia began a 3-year, £3,000,000 commitment to funding the national Trials Acceleration Programme (TAP).
The TAP Network allows patients to be connected with world-class and potentially lifesaving treatment that would otherwise not be available to them through standard care.
The TAP network allows a catchment area of over 20,000,000 patients to be connected with world-class and potentially lifesaving treatments that would otherwise not be available to them through standard care – with over 40,000 people diagnosed with blood cancer every year.
As of March 2023, the TAP Network has now been able to expand from 12 to 15 centres across the UK.
Four new hospitals will join the network – Bristol Haematology and Oncology Centre, the Freeman Hospital in Newcastle, the Manchester Royal Infirmary and The Royal Marsden – and join Centres in Belfast, Glasgow, Manchester, Leeds, Cardiff, Nottingham, Birmingham, Oxford, Southampton and London (x2) to form the TAP Network.
Dr Emma Searle, a Consultant Haematologist based at The Christie Manchester and Dr Richard Kelly, a Consultant Haematologist based at Leeds Teaching Hospital talk about just how important Cure Leukaemia is, and how much of a difference the TAP Network makes.